Minimal residual disease (MRD) as a prognostic factor for acute myeloid leukemia (AML)
Gerrit Jan Schuurhuis
ADCT-402 - a drug to watch
REMoDL-B clinical trial: results presented at ASH 2015
Reporting positive treatment outcomes with bendamustine + rituximab in indolent lymphomas
Mathias J Rummel
Panel discussion on novel therapies and targets for lymphoma
John Gribben et al.